Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 14 art units • 16 examiners • 0 of 16 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Albert Einstein College of Medicine has 16 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 16 distinct examiners and 14 distinct art units. LUONG, PETER is the busiest examiner, with 1 pending matter, so the actions are widely distributed among examiners with some art-unit overlap.
The prosecution record calls for disciplined portfolio coordination, including consistent terminology, disclosure mapping, and tracking of examiner positions. The higher examiner count than art-unit count indicates that some art units receive more than one matter, which may support technical grouping without eliminating application-specific review. Since no examiner handles more than one identified matter, counsel should develop each response against its own cited record and claim scope.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (19%) |
| §103 only | 2 (12%) |
| §102 only | 1 (6%) |
| §112 only | 3 (19%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 6 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUONG, PETER | 1 | 69.4% | +26.2% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
| HALL, DEANNA K | 1 | 75.7% | +15.3% |
| EVANS, TRISTAN ISAAC | 1 | 35.5% | +51.8% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17372080 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION | ABRAHAM, AMJAD A | 134d overdue |
| 18282671 | CLINICAL DECISION SUPPORT SYSTEMS EMPLOYING REVERSE PHENOTYPING | EVANS, TRISTAN ISAAC | 1d overdue |
| 18250685 | REPORTER MYCOBACTERIOPHAGE, ASSAYS AND METHODS COMPRISING THE REPORTER MYCOBACTERIOPHAGE | WANG, RUIXUE | 26d |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | BARRON, SEAN C | — |
| 18405839 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | MOSELEY II, NELSON B | — |
| 18560828 | VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES | SULLIVAN, STEPHANIE LAUREN | — |
| 17905323 | COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED CELL MODULATION | QIAN, CELINE X | — |
| 18043441 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | HIRAKIS, SOPHIA P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282671 | CLINICAL DECISION SUPPORT SYSTEMS EMPLOYING REVERSE PHENOTYPING | EVANS, TRISTAN ISAAC | 1d overdue |
| 18247152 | METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS | POLIAKOVA-GEORGAN, EKATERINA | 14d |
| 18250685 | REPORTER MYCOBACTERIOPHAGE, ASSAYS AND METHODS COMPRISING THE REPORTER MYCOBACTERIOPHAGE | WANG, RUIXUE | 26d |
| 18658055 | LOW INTENSITY FOCUSED ULTRASOUND FOR TREATING CANCER AND METASTASIS | LUONG, PETER | 27d |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | BARRON, SEAN C | — |
| 18405839 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | MOSELEY II, NELSON B | — |
| 18560828 | VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES | SULLIVAN, STEPHANIE LAUREN | — |
| 18559495 | SINGLE-COMPONENT NEAR-INFRARED OPTOGENETIC SYSTEMS FOR GENE TRANSCRIPTION REGULATION | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1623 | 2 |
| 3797 | 1 |
| 1653 | 1 |
| 1642 | 1 |
| 1635 | 1 |
| 1657 | 1 |
| 3783 | 1 |
| 3683 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18658055 | LOW INTENSITY FOCUSED ULTRASOUND FOR TREATING CANCER AND METASTASIS | LUONG, PETER | 3797 | §103Other | Final Rejection | 27d | Pending | May 08, 2024 |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18405839 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | MOSELEY II, NELSON B | 1642 | §101§103Other | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18560828 | VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES | SULLIVAN, STEPHANIE LAUREN | 1635 | §101§112DP | Final Rejection | — | Pending | Nov 14, 2023 |
| 18559495 | SINGLE-COMPONENT NEAR-INFRARED OPTOGENETIC SYSTEMS FOR GENE TRANSCRIPTION REGULATION | SWIFT, CANDICE LEE | 1657 | §112 | Final Rejection | — | Pending | Nov 07, 2023 |
| 18487659 | NITRIC OXIDE-RELEASING DEVICE | HALL, DEANNA K | 3783 | §102 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18282671 | CLINICAL DECISION SUPPORT SYSTEMS EMPLOYING REVERSE PHENOTYPING | EVANS, TRISTAN ISAAC | 3683 | §101§103 | Final Rejection | 1d overdue | Pending | Sep 18, 2023 |
| 17905323 | COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED CELL MODULATION | QIAN, CELINE X | 1637 | §103§112 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18250685 | REPORTER MYCOBACTERIOPHAGE, ASSAYS AND METHODS COMPRISING THE REPORTER MYCOBACTERIOPHAGE | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | 26d | Pending | Apr 26, 2023 |
| 18247152 | METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112 | Final Rejection | 14d | Pending | Mar 29, 2023 |
| 18044606 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | VALLE, ERNESTO | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Mar 09, 2023 |
| 18043441 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Final Rejection | — | Pending | Feb 28, 2023 |
| 18041262 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103 | Final Rejection | 35d overdue | Pending | Feb 10, 2023 |
| 17905325 | A METHOD TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS (CAR-T CELLS) FROM PATHOGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES TO ENABLE THE SUBSEQUENT IN VIVO MODULATION OF THEIR FUNCTIONAL ACTIVITY | ABUZEINEH, HANAN ISAM | 1633 | §102§103 | Final Rejection | — | Pending | Aug 30, 2022 |
| 17855772 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | MOORE, SUSANNA | 1624 | §112Other | Final Rejection | 28d | Pending | Jun 30, 2022 |
| 17372080 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION | ABRAHAM, AMJAD A | 1663 | §103§112 | Non-Final OA | 134d overdue | Pending | Jul 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlbert Einstein College of Medicine has 16 pending office actions as of October 2026, spread across 14 art units and 16 examiners.
Peter Luong has the most, with 1 of Albert Einstein College of Medicine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
